EMCURE Q1 FY27 results at a glance
EMCURE PHARMACEUTICALS L Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹2,580 cr |
|---|
| Revenue YoY | +22.8% |
|---|
| Operating profit | ₹398 cr |
|---|
| Operating margin | 15.4% |
|---|
| Net profit | ₹294 cr |
|---|
| Net profit YoY | +42.1% |
|---|
| Net profit QoQ | +20.8% |
|---|
| Net margin | 11.4% |
|---|
| Basic EPS | ₹15.50 |
|---|
| TTM revenue | ₹9,683 cr |
|---|
| TTM net profit | ₹1,011 cr |
|---|
| TTM net margin | 10.4% |
|---|
EMCURE Q1 FY27 results: what the numbers say
EMCURE PHARMACEUTICALS L (EMCURE) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹2,580 cr and a net profit of ₹294 cr, translating into earnings per share of ₹15.50.
Compared with the same quarter a year earlier, revenue grew strongly by +22.8% and net profit grew strongly by +42.1%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹398 cr, an operating margin of 15.4% versus 14.5% a year ago — a gain of 0.9 percentage points.
EMCURE quarter-wise results table
Revenue
₹2,580 cr
+22.8% YoY
Net profit
₹294 cr
+42.1% YoY
Operating profit
₹398 cr
+30.9% YoY
EMCURE PHARMACEUTICALS L (EMCURE) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹2,580 cr | ₹398 cr | ₹294 cr | 15.4% | 11.4% | ₹15.50 | +42.1% | +20.8% |
| Q4 FY262026-03-31 | ₹2,470 cr | ₹379 cr | ₹243 cr | 15.4% | 9.9% | ₹12.84 | — | +5.6% |
| Q3 FY262025-12-31 | ₹2,363 cr | ₹355 cr | ₹231 cr | 15.0% | 9.8% | ₹12.16 | — | -5.3% |
| Q2 FY262025-09-30 | ₹2,270 cr | ₹334 cr | ₹243 cr | 14.7% | 10.7% | ₹12.85 | — | +17.6% |
| Q1 FY262025-06-30 | ₹2,101 cr | ₹304 cr | ₹207 cr | 14.5% | 9.9% | ₹10.92 | — | — |
| TTM (last 4 quarters) | ₹9,683 cr | ₹1,468 cr | ₹1,011 cr | 15.2% | 10.4% | ₹53.35 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
EMCURE quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
EMCURE PHARMACEUTICALS L quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹2,580 cr | ₹2,470 cr | ₹2,363 cr | ₹2,270 cr | ₹2,101 cr |
|---|
| Total expenses | ₹2,182 cr | ₹2,090 cr | ₹2,008 cr | ₹1,935 cr | ₹1,796 cr |
|---|
| Gross profit | ₹1,507 cr | ₹1,467 cr | ₹1,401 cr | ₹1,380 cr | ₹1,299 cr |
|---|
| Operating profit (EBIT) | ₹398 cr | ₹379 cr | ₹355 cr | ₹334 cr | ₹304 cr |
|---|
| Operating margin | 15.4% | 15.4% | 15.0% | 14.7% | 14.5% |
|---|
| Interest cost | ₹31.54 cr | ₹46.4 cr | ₹37.98 cr | ₹32.54 cr | ₹26.76 cr |
|---|
| Profit before tax | ₹394 cr | ₹341 cr | ₹314 cr | ₹341 cr | ₹291 cr |
|---|
| Tax expense | ₹101 cr | ₹97.44 cr | ₹82.42 cr | ₹90.05 cr | ₹75.97 cr |
|---|
| Effective tax rate | 25.7% | 28.6% | 26.3% | 26.4% | 26.1% |
|---|
| Net profit (PAT) | ₹294 cr | ₹243 cr | ₹231 cr | ₹243 cr | ₹207 cr |
|---|
| Net profit margin | 11.4% | 9.9% | 9.8% | 10.7% | 9.9% |
|---|
| Basic EPS | ₹15.50 | ₹12.84 | ₹12.16 | ₹12.85 | ₹10.92 |
|---|
| Diluted EPS | ₹15.50 | ₹12.84 | ₹12.16 | ₹12.85 | ₹10.92 |
|---|
EMCURE results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +22.8% | — | — | — | — |
|---|
| Revenue QoQ | +4.5% | +4.5% | +4.1% | +8.1% | — |
|---|
| Operating profit YoY | +30.9% | — | — | — | — |
|---|
| Operating profit QoQ | +5.1% | +6.7% | +6.3% | +9.9% | — |
|---|
| Net profit YoY | +42.1% | — | — | — | — |
|---|
| Net profit QoQ | +20.8% | +5.6% | -5.3% | +17.6% | — |
|---|
| EPS YoY | +41.9% | — | — | — | — |
|---|
| EPS QoQ | +20.7% | +5.6% | -5.4% | +17.7% | — |
|---|
EMCURE annual results history
Full-year performance for EMCURE PHARMACEUTICALS L, useful for reading each quarter in context.
EMCURE PHARMACEUTICALS L annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹9,116 cr | ₹7,808 cr | ₹6,582 cr | ₹5,931 cr |
|---|
| Total expenses | ₹7,742 cr | ₹6,724 cr | ₹5,665 cr | ₹4,990 cr |
|---|
| Gross profit | ₹5,217 cr | ₹4,486 cr | ₹3,972 cr | ₹3,523 cr |
|---|
| Operating profit (EBIT) | ₹1,374 cr | ₹1,085 cr | ₹917 cr | ₹941 cr |
|---|
| Operating margin | 15.1% | 13.9% | 13.9% | 15.9% |
|---|
| Interest cost | ₹123 cr | ₹140 cr | ₹201 cr | ₹163 cr |
|---|
| Profit before tax | ₹1,287 cr | ₹971 cr | ₹727 cr | ₹747 cr |
|---|
| Tax expense | ₹346 cr | ₹264 cr | ₹200 cr | ₹185 cr |
|---|
| Effective tax rate | 26.9% | 27.2% | 27.5% | 24.8% |
|---|
| Net profit (PAT) | ₹924 cr | ₹681 cr | ₹498 cr | ₹532 cr |
|---|
| Net profit margin | 10.1% | 8.7% | 7.6% | 9.0% |
|---|
| Basic EPS | ₹48.77 | ₹36.43 | ₹27.57 | ₹29.43 |
|---|
| Diluted EPS | ₹48.77 | ₹36.43 | ₹27.57 | ₹29.43 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹2,580 cr against ₹2,101 cr in Q1 FY26, and ₹2,470 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +4.5%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹2,182 cr, or 84.6% of revenue, with operating profit grew +30.9% year on year.
Margins, tax and profitability
Net profit of ₹294 cr works out to a net margin of 11.4% compared with 9.9% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, EMCURE PHARMACEUTICALS L reported profit before tax of ₹394 cr, a tax charge of ₹101 cr (effective rate 25.7%), interest cost of ₹31.54 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹243 cr in Q4 FY26 to ₹294 cr in Q1 FY27, a change of +20.8%.
Trailing twelve months and annual context
Across the trailing four quarters EMCURE PHARMACEUTICALS L has generated revenue of ₹9,683 cr and net profit of ₹1,011 cr, a trailing net margin of 10.4%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹9,116 cr with net profit of ₹924 cr and EPS of ₹48.77, versus the prior year where revenue grew +16.7% and profit grew +35.7%.
What to watch in the next EMCURE quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
EMCURE PHARMACEUTICALS L has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
EMCURE results coverage
No results report published for EMCURE yet — our desk covers each quarter within minutes of the filing.
More on EMCURE
EMCURE quarterly results FAQs
What were EMCURE PHARMACEUTICALS L (EMCURE) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), EMCURE PHARMACEUTICALS L reported revenue of ₹2,580 cr and net profit of ₹294 cr, a change of +42.1% year on year on +22.8% revenue growth. EPS stood at ₹15.50.
What is EMCURE profit margin in Q1 FY27?
EMCURE PHARMACEUTICALS L posted a net profit margin of 11.4% and an operating margin of 15.4% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹9,683 cr and net profit ₹1,011 cr.
Did EMCURE results beat the previous quarter?
EMCURE PHARMACEUTICALS L net profit changed +20.8% quarter on quarter, from ₹243 cr in Q4 FY26 to ₹294 cr in Q1 FY27.
When are EMCURE PHARMACEUTICALS L (EMCURE) quarterly results?
EMCURE PHARMACEUTICALS L has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see EMCURE latest quarterly results?
Results coverage for EMCURE will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the EMCURE stock page.
What is EMCURE PHARMACEUTICALS L annual revenue and profit?
For FY26, EMCURE PHARMACEUTICALS L reported full-year revenue of ₹9,116 cr and net profit of ₹924 cr, with EPS of ₹48.77.
How many quarterly results has EMCURE declared recently?
Past results dates for EMCURE will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 10 Sept 2026. For information only, not investment advice.
